Abstract
EGFR-TKIs offer significantly greater efficacy than chemotherapy in patients with TKI sensitive EGFR mutations, TKIs are now the first line therapy for advanced lung adenocarcinoma in patients with sensitive EGFR mutations. Despite the high efficacy of these kinase inhibitors, radical cure of stage IV NSCLC remains an unachieved goal because invariably, almost all patients develop acquired resistance within one to several years. Constant efforts have been made to search strategy for overcoming resistance to kinase inhibitors, such as combined anti-vascular or combined chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
